The latest research on long-acting ART shows benefits even among the unsuppressed; meanwhile, early proof-of-concept results on a twice-yearly injection raise hopes.
Postexposure prophylaxis with doxycycline has been shown to significantly reduce the risk of STIs in men and transgender women. Now a study looks at its efficacy in cisgender women taking HIV PrEP.
Data confirm the effectiveness and safety of dolutegravir and raltegravir for infants, children, and adolescents living with HIV, but researchers say that long-term monitoring is needed.